Q-omics provides the consensus-scored PKD1P1 profile across patient tissues and cancer cell-line models. PKD1P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PKD1P1 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, PKD1P1 RNA expression shows 16,912 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, THCA, and THYM as cancer lineages where PKD1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKD1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKD1P1 survival associations across molecular data types. PKD1P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKD1P1 RNA expression–survival associations across cancer types. High PKD1P1 expression shows unfavorable associations in LIHC, LUAD, THCA and KIRC, but favorable associations in UCS and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PKD1P1 RNA expression.
This table summarizes PKD1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PKD1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKD1P1 shows lower tumor expression in THCA and UCEC and higher tumor expression in CHOL, COAD, LUSC and LIHC. The THCA box plot shows higher PKD1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.015, t-test p = .001).
This table shows molecular features associated with PKD1P1 in patient tissues and cancer cell lines. In patient samples, PKD1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PKD1P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and NCI60_ALL.
